Sign up for our monthly newsletter!
Get the latest information and inspirational stories for caregivers, delivered directly to your inbox.
The Jerusalem Post
After multiple clinical trials, researchers are becoming increasingly confident in sodium selenate's ability to halt cognitive decline in dementia patients. Sodium selenate could be the answer to dementia treatment that medical professionals have been searching for. This new drug could provide crucial treatment for patients exhibiting early stages of behavioral variant frontotemporal dementia, most common in people aged 65 and under.
See full story at The Jerusalem Post